Comparison of stem cell therapies for acute kidney injury.

Related Articles

Comparison of stem cell therapies for acute kidney injury.

Am J Stem Cells. 2016;5(1):1-10

Authors: Barnes CJ, Distaso CT, Spitz KM, Verdun VA, Haramati A

Abstract
Acute kidney injury (AKI) is the rapid onset of decreased kidney function that ultimately increases mortality and morbidity. Stem cell research is a promising avenue for curative and preventative therapies of kidney injury, however, there are many types of stem cells under investigation. Currently there is no research to compare the value of one stem cell method over another. Induced pluripotent stem cells (iPSCs) and spermatogonial stem cells (SSCs) have been shown to differentiate into renal cells, though further clinical research is needed to fully explore potential therapeutic strategies. Mesenchymal stem cells (MSCs) have long been investigated in the preclinical setting and have recently been successful in Phase I clinical trials. MSCs may represent a promising new therapeutic approach to treat AKI as they demonstrate renoprotective effects post-injury via the secretion of promitotic, anti-apoptotic, anti-inflammatory, and immunomodulatory factors. Given the most current research, MSCs appear to offer a promising course of treatment for AKI.

PMID: 27335697 [PubMed]

from Head and Neck on PubMed via xlomafota13 on Inoreader http://ift.tt/291yQqk


http://ift.tt/28XguGF